EcoDrugPlus

Provisional Ortholog Of C-Reactive Protein

Ensembl ID : ENSXETG00000046752
Gene Symbol: XB5856184
5 View Cross-references
555 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Provisional Ortholog Of Cathepsin K

Ensembl ID : ENSXETG00000008916
Gene Symbol: XB986811
5 View Cross-references
122 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Provisional Ortholog Of Neuropeptide Y Receptor Y4

Ensembl ID : ENSXETG00000036571
Gene Symbol: XB996286
7 Enzyme and pathways 5 View Cross-references
116 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2x, Ligand Gated Ion Channel, 7

Ensembl ID : ENSXETG00000044575
Gene Symbol: P2RX7
5 View Cross-references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y, G-Protein Coupled, 1

Ensembl ID : ENSXETG00000027713
Gene Symbol: P2RY1
12 Enzyme and pathways 5 View Cross-references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y, G-Protein Coupled, 12

Ensembl ID : ENSXETG00000020623
Gene Symbol: P2RY12
12 Enzyme and pathways 5 View Cross-references
180 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pyrimidinergic Receptor P2y, G-Protein Coupled, 4

Ensembl ID : ENSXETG00000023193
Gene Symbol: P2RY4
8 Enzyme and pathways 5 View Cross-references
165 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Receptor (G Protein-Coupled) Activity Modifying Protein 1

Ensembl ID : ENSXETG00000010906
Gene Symbol: RAMP1
5 View Cross-references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSXETG00000011415
Gene Symbol: RIPK1
5 View Cross-references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Regulatory Associated Protein Of Mtor, Complex 1

Ensembl ID : ENSXETG00000013410
Gene Symbol: RPTOR
21 Enzyme and pathways 5 View Cross-references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Renin

Ensembl ID : ENSXETG00000007042
Gene Symbol: REN
3 Enzyme and pathways 5 View Cross-references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ret Proto-Oncogene

Ensembl ID : ENSXETG00000005422
Gene Symbol: RET
8 Enzyme and pathways 5 View Cross-references
81 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).